JP2024539089A - 修飾複製可能rnaの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用 - Google Patents

修飾複製可能rnaの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用 Download PDF

Info

Publication number
JP2024539089A
JP2024539089A JP2024523403A JP2024523403A JP2024539089A JP 2024539089 A JP2024539089 A JP 2024539089A JP 2024523403 A JP2024523403 A JP 2024523403A JP 2024523403 A JP2024523403 A JP 2024523403A JP 2024539089 A JP2024539089 A JP 2024539089A
Authority
JP
Japan
Prior art keywords
rrna
rna
modified
molecule
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539089A5 (cg-RX-API-DMAC7.html
Inventor
ティム バイセルト,
マリオ ペルコビッチ,
ステファニー ガウレッタ,
パトリック ソーン,
シルケ ブリル,
エヴリン ネット,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
BioNTech SE
Original Assignee
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, BioNTech SE filed Critical Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Publication of JP2024539089A publication Critical patent/JP2024539089A/ja
Publication of JP2024539089A5 publication Critical patent/JP2024539089A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2024523403A 2021-10-18 2022-10-17 修飾複製可能rnaの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用 Pending JP2024539089A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2021078828 2021-10-18
EPPCT/EP2021/078828 2021-10-18
PCT/EP2022/078869 WO2023066874A1 (en) 2021-10-18 2022-10-17 Methods for determining mutations for increasing modified replicable rna function and related compositions and their use

Publications (2)

Publication Number Publication Date
JP2024539089A true JP2024539089A (ja) 2024-10-28
JP2024539089A5 JP2024539089A5 (cg-RX-API-DMAC7.html) 2025-10-22

Family

ID=78483247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523403A Pending JP2024539089A (ja) 2021-10-18 2022-10-17 修飾複製可能rnaの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用

Country Status (7)

Country Link
US (1) US20250250626A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419708A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539089A (cg-RX-API-DMAC7.html)
CN (1) CN118451194A (cg-RX-API-DMAC7.html)
AU (1) AU2022372325A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234214A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023066874A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4522754A1 (en) * 2022-05-12 2025-03-19 Sunvax MRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
WO2025040709A1 (en) 2023-08-24 2025-02-27 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
CN122514603A (zh) * 2023-11-02 2026-08-04 安普利特治疗公司 包含经化学修饰的核碱基的反式扩增rna
WO2025129137A1 (en) * 2023-12-14 2025-06-19 Amplitude Therapeutics, Inc. Two-component platform for trans amplifying rna (tarna) vaccination
CN120379688A (zh) * 2024-01-24 2025-07-25 南京金斯瑞生物科技有限公司 一种自复制rna及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119827A1 (en) 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
US8153773B2 (en) 2007-06-19 2012-04-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
CN101848936B (zh) 2007-08-20 2017-05-03 葛兰素集团有限公司 生产方法
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
AU2018333530B2 (en) * 2017-09-13 2024-05-30 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
WO2020146690A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Methods for in vitro evolution of rna replicons
JP2023521662A (ja) * 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン

Also Published As

Publication number Publication date
CA3234214A1 (en) 2023-04-27
WO2023066874A1 (en) 2023-04-27
EP4419708A1 (en) 2024-08-28
AU2022372325A1 (en) 2024-05-02
CN118451194A (zh) 2024-08-06
US20250250626A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
JP7465310B2 (ja) 多用途性且つ効率的な遺伝子発現のためのrnaレプリコン
RU2752580C2 (ru) Транс-реплицирующая рнк
JP7769644B2 (ja) 多用途かつ効率的な遺伝子発現のためのrnaレプリコン
US20250250626A1 (en) Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
US20250281602A1 (en) Replicon Compositions and Methods of Using Same for the Treatment of Diseases
US20250236883A1 (en) Modified replicable rna and related compositions and their use
TW202526021A (zh) 包括高度活性反式擴增複製酶之系統及組合物
HK40094277A (en) Rna replicon for versatile and efficient gene expression
HK40004174B (en) Trans-replicating rna
HK40004174A (en) Trans-replicating rna
HK40000763A (en) Rna replicon for versatile and efficient gene expression
HK40000763B (en) Rna replicon for versatile and efficient gene expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251014